2020 Conference on Retroviruses and Opportunistic Infections*

March 8-11, 2020; Boston, Massachusetts
Get up to date on the latest HIV data with rapid Capsule Summaries, video highlights, downloadable slidesets, on-demand audio, and expert analysis covering key studies from Boston.

Highlights

Capsule Summary Slidesets

Rapid ART initiation at CrescentCare Health Clinic within 72 hrs of diagnosis and prior to obtaining laboratory results was effective and well tolerated in adults and young persons (18-24 yrs) with HIV.

Released: March 13, 2020

Higher rates of virologic suppression at delivery and fewer adverse birth outcomes in treatment-naive women initiating DTG-based ART vs EFV/FTC/TDF during pregnancy.

Released: March 14, 2020

Phase III data demonstrate that long-acting cabotegravir + rilpivirine injections every 2 months is noninferior to monthly injections at Week 48 in virologically suppressed patients with no prior virologic failure.

Released: March 10, 2020

Long-term pooled analysis of Studies 1489 and 1490 demonstrated comparable efficacy and safety, including renal and bone outcomes, in older and younger patients initiating BIC/FTC/TAF vs DTG-based 3-drug regimens.

Released: March 13, 2020

Switch to monthly injections of long-acting cabotegravir + rilpivirine after 20-week induction with oral 3-drug ART in treatment-naive patients noninferior to continued oral 3-drug ART for the maintenance of virologic suppression at Week 96 and demonstrates higher patient-reported satisfaction.

Released: March 11, 2020

Detailed analysis of confirmed virologic withdrawals shows low risk of treatment-emergent resistance in treatment-naive patients treated with DTG/3TC for initial ART.

Released: March 13, 2020

Changes in weight, body fat, BMD, and fasting lipid parameters were comparable among varying doses of islatravir + DOR vs DOR/3TC/TDF at Week 48 in ART-naive patients.

Released: March 14, 2020

Increases in adipose tissue and predicted 10-year risk of diabetes significantly higher with use of DTG + FTC/TAF compared with DTG + FTC/TDF or EFV/FTC/TDF in treatment-naive patients initiating ART in South Africa.

Released: March 13, 2020

Post hoc analysis found that patients initiating EFV-based ART who were categorized by CYP2B6 genotyping as slow metabolizers had less weight gain compared with extensive metabolizers and those initiating DTG-based ART.

Released: March 14, 2020

Longer-term follow-up demonstrates continued noninferior efficacy and more favorable bone and renal safety profile of FTC/TAF vs FTC/TDF for HIV prevention in MSM and transgender women.

Released: March 15, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue